» Articles » PMID: 22186140

MiR-20a Encoded by the MiR-17-92 Cluster Increases the Metastatic Potential of Osteosarcoma Cells by Regulating Fas Expression

Overview
Journal Cancer Res
Specialty Oncology
Date 2011 Dec 22
PMID 22186140
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of osteosarcoma cells to form lung metastases has been inversely correlated to cell surface Fas expression. Downregulation of Fas allows osteosarcoma cells to circumvent FasL-mediated apoptosis upon entrance into the FasL(+) lung microenvironment. However, the mechanism of Fas regulation remains unclear. Here, we show that miRNA plays a role in the downregulation of Fas expression in osteosarcoma. Expression levels of several members of the miR-17-92 cluster including miR-20a and miR-19a were found to be higher in metastatic low-Fas-expressing LM7 cells than in the parental nonmetastatic high-Fas-expressing SAOS-2 cells. We also found an inverse correlation between Fas and miR-20a expression in all 8 cell lines derived from patient samples. Overexpression of miR-20a consistently resulted in the downregulation of Fas expression in SAOS-2 cells and thus in decreased sensitivity to FasL. Conversely, inhibiting miR-20a in LM7 cells increased Fas expression and their sensitivity to FasL. Mice injected with LM7 stably transfected with anti-miR-20a had fewer metastases than those with control plasmids. Taken together, our findings suggest that miR-20a, encoded by miR-17-92, downregulates Fas expression in osteosarcoma, thus contributing to the metastatic potential of osteosarcoma cells by altering the phenotype and allowing survival in the FasL(+) lung microenvironment.

Citing Articles

miRNA-214-3p stimulates carcinogen-induced mammary epithelial cell apoptosis in mammary cancer-resistant species.

Harman R, Das S, Kanke M, Sethupathy P, Van de Walle G Commun Biol. 2023; 6(1):1006.

PMID: 37789172 PMC: 10547694. DOI: 10.1038/s42003-023-05370-4.


The Role of FAS Receptor Methylation in Osteosarcoma Metastasis.

Sun J, Chow W, Xu G, Hicks M, Nakka M, Shen J Int J Mol Sci. 2023; 24(15).

PMID: 37569529 PMC: 10418590. DOI: 10.3390/ijms241512155.


Noncoding RNAs in apoptosis: identification and function.

Tuncel O, Kara M, Yaylak B, Erdogan I, Akgul B Turk J Biol. 2023; 46(1):1-40.

PMID: 37533667 PMC: 10393110. DOI: 10.3906/biy-2109-35.


Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming.

Yang Y, Peng Z, Flores E, Kleinerman E Cancers (Basel). 2022; 14(17).

PMID: 36077845 PMC: 9454976. DOI: 10.3390/cancers14174310.


Antiapoptotic Protein FAIM2 is targeted by miR-3202, and DUX4 via TRIM21, leading to cell death and defective myogenesis.

Soliman H, Toso E, Darwish I, Ali S, Kyba M Cell Death Dis. 2022; 13(4):405.

PMID: 35468884 PMC: 9038730. DOI: 10.1038/s41419-022-04804-x.


References
1.
Koshkina N, Rao-Bindal K, Kleinerman E . Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer. 2011; 117(15):3457-67. PMC: 3136583. DOI: 10.1002/cncr.25884. View

2.
Schickel R, Park S, Murmann A, Peter M . miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010; 38(6):908-15. PMC: 2904349. DOI: 10.1016/j.molcel.2010.05.018. View

3.
Koshkina N, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman E . Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007; 5(10):991-9. DOI: 10.1158/1541-7786.MCR-07-0007. View

4.
Xiao C, Srinivasan L, Calado D, Patterson H, Zhang B, Wang J . Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4):405-14. PMC: 2533767. DOI: 10.1038/ni1575. View

5.
Petrocca F, Visone R, Onelli M, Shah M, Nicoloso M, De Martino I . E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008; 13(3):272-86. DOI: 10.1016/j.ccr.2008.02.013. View